EUVIMEDEUVIMED entdecken
Crossref

Drug-induced hyperprolactinemia: mechanism of development, features of diagnosis and treatment

L. K. Dzeranova, S. Y. Vorotnikova, A. S. Shutova, E. A. Pigarova, M. I. Yevloyeva

Obesity and metabolism · 14.11.2023 · 20 (3) · 251-258

DOI: 10.14341/omet13036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity and metabolism, online erschienen am 14.11.2023. Verfasst von L. K. Dzeranova und 4 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

One of the causes of non-tumor related hyperprolactinemia is taking a medications. Physicians of various specialties, such as cardiologists, gastroenterologists, endocrinologists, and neurologists, encounter hyperprolactinemia as a side effect of drug therapy in their practice, but it is most often observed in the practice of a psychiatrist when treating patients with psychotropic medications. Over the past few years, there has been an increase in the frequency of prescriptions of antidepressants and neuroleptics due to post-COVID-19 syndrome, anxiety and stress caused by the pandemic of a new coronavirus infection. There is also a predisposition to the development of hyperprolactinemia on the background of taking neuroleptics due to genetic features of patients. Currently, there is no established common algorithm for diagnosis and treatment of drug-induced hyperprolactinemia in the world. Based on a review of foreign and domestic literature, the article discusses in detail the mechanisms of development and various approaches to the correction of iatrogenic (drug-induced) hyperprolactinemia, assesses the prolactogenic activity of neuroleptics, and proposes algorithms for prolactin monitoring and correction of hyperprolactinemia using dopamine agonists. Often the tactics of management of such patients need to be discussed by a team of specialized physicians.

Zitieren

APA

Dzeranova, L. K., Vorotnikova, S. Y., Shutova, A. S., Pigarova, E. A., & Yevloyeva, M. I. (2023). Drug-induced hyperprolactinemia: mechanism of development, features of diagnosis and treatment. Obesity and metabolism, 20(3), 251-258. https://doi.org/10.14341/omet13036

Vancouver

Dzeranova LK, Vorotnikova SY, Shutova AS, Pigarova EA, Yevloyeva MI. Drug-induced hyperprolactinemia: mechanism of development, features of diagnosis and treatment. Obesity and metabolism. 2023;20(3):251-258. doi:10.14341/omet13036

BibTeX
@article{Dzeranova2023,
  author = {Dzeranova, L. K. and Vorotnikova, S. Y. and Shutova, A. S. and Pigarova, E. A. and Yevloyeva, M. I.},
  title = {Drug-induced hyperprolactinemia: mechanism of development, features of diagnosis and treatment},
  journal = {Obesity and metabolism},
  year = {2023},
  volume = {20},
  number = {3},
  pages = {251--258},
  doi = {10.14341/omet13036}
}
Kostenlos starten →